CLINIGEN GROUP PLC LS-001

CLINIGEN GROUP PLC LS-001

Action · GB00B89J2419 · A1J440 (XLON)
Aperçu
Analyse alimentée par l’IA
Analyse fondamentale
Découvrez ce que disent vraiment les chiffres — avant le marché
Analyser maintenant
Sentiment des actualités
Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?
Analyser maintenant
Acheter / Conserver / Vendre
Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.
Analyser maintenant
Évaluation des risques
Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.
Analyser maintenant
Juste valeur
Cette action est-elle bon marché, correctement valorisée ou surévaluée ?
Analyser maintenant
Dernières analyses d’IA sur CLINIGEN GROUP PLC LS-001
Pas de cours
Fonds investis

Les fonds suivants ont investi dans CLINIGEN GROUP PLC LS-001 :

Fonds
iShares MSCI UK Small Cap UCITS ETF GBP (Acc)
Vol. en millions
1.081,40
Part (%)
0,18 %
Profil de l'entreprise pour CLINIGEN GROUP PLC LS-001 Action
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Données de l'entreprise

Nom CLINIGEN GROUP PLC LS-001
Société Clinigen Group plc
Site web https://www.clinigengroup.com
Marché d'origine XLON London
WKN A1J440
ISIN GB00B89J2419
Type de titre Action
Secteur Healthcare
Industrie Medical - Distribution
PDG Shaun Chilton
Pays Royaume-Uni
Devise GBP
Employés 1,0 T
Adresse Pitcairn House, Crown Square, First Avenue, DE14 2WW Staffordshire
Date d'introduction en bourse 2012-09-25
Dividendes de 'CLINIGEN GROUP PLC LS-001'
Date ex-dividende Dividende par action
02.12.2021 5,46 GBX
18.03.2021 2,15 GBX
05.11.2020 5,46 GBX
19.03.2020 2,15 GBX
07.11.2019 4,75 GBX
21.03.2019 1,95 GBX
08.11.2018 3,84 GBX
22.03.2018 1,76 GBX
09.11.2017 3,40 GBX
23.03.2017 1,60 GBX

Symboles boursiers

Nom Symbole
London CLIN.L
Autres actions
Les investisseurs qui détiennent CLINIGEN GROUP PLC LS-001 ont également les actions suivantes dans leur portefeuille :
AON CORP 19/22
AON CORP 19/22 Obligation
AUSTRALIA & NEW ZEALAND BANKING GROUP LD CALL ZERO CPN NTS 02/04/43
AUSTRALIA & NEW ZEALAND BANKING GROUP LD CALL ZERO CPN NTS 02/04/43 Obligation